Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT03146416
- Locations
- 🇺🇸
WCCT Global, Inc., Cypress, California, United States
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 138
- Registration Number
- NCT03132636
- Locations
- 🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Overlook Medical Center, Summit, New Jersey, United States
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT03115996
- Locations
- 🇬🇧
Covance Clinical Research Unit (CRU) Ltd., Leeds, United Kingdom
Study of REGN3500 and Dupilumab in Patients With Asthma
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03112577
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
🇬🇧Celerion, Belfast, United Kingdom
🇬🇧Hammersmith Medicine Research, London, United Kingdom
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 712
- Registration Number
- NCT03088540
- Locations
- 🇺🇦
Clinical Study Site 2, Kyiv, Ukraine
🇹🇷Clinical Study Site 3, İzmir, Turkey
🇧🇷Clinical Study Site #3, São Paulo, Brazil
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT03084640
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 251
- Registration Number
- NCT03054428
- Locations
- 🇨🇦
Regeneron Investigational Site, Windsor, Ontario, Canada
🇨🇦Regeneron Research Site, Richmond Hill, Ontario, Canada
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT03050151
- Locations
- 🇺🇸
Regeneron Investigational Site, Tacoma, Washington, United States
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 333
- Registration Number
- NCT03005782
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸California Pacific Medical Center (CPMC), San Francisco, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT03002376
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of